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Introduction 
 
Robust and generalizable data, and the full and transparent reporting of those data, are key to 
drawing the right conclusions, deciding on next experimental steps and achieving scientific progress 
(Steckler, 2015). Notably, many scientific articles, not just those in the field of psychopharmacology, 
lack sufficient methodological detail (Vasilevsky et al. 2013) and important information on 
experimental design (Bebarta et al., 2003; Hirst et al., 2014; Kilkenny et al., 2009; Macleod et al., 
2015; McCance, 1995; Vesterinen et al., 2011). These details are essential to allow the reader to 
understand what exactly was done in a study, to judge the quality of the data, and to repeat the 
study. Accordingly, many scientific journals are emphasizing  guidelines for the full and transparent 
reporting of data (Curtis and Abernethy, 2015; Curtis et al., 2015; Kenall et al., 2015; Kilkenny et al., 
2011; Nature Publishing Group, 2014; Nosek et al., 2015). 
 
To help authors in Psychopharmacology to continue to produce high quality articles containing all 
the information necessary to judge the rigor of a study, to improve reporting practice and to 
enhance the impact of articles published in the journal, the editors of Psychopharmacology have 
agreed on the following guidelines, in accordance with Springer’s long-standing policy on the full and 
transparent reporting of data and experimental design: 
 
Abstract 
 
The Abstract should contain the purpose, methods, results and conclusions.  In the results, the effect 
size should be included if possible. 
 
 Experimental design and statistics 
 
The Methods section should provide information sufficient to allow replication of the work and full 
details on the statistical methods used. The figure legends should provide information essential to 
interpreting the data presented. The following information should be included in the Methods: 
 
1. The exact sample size (n) for each experimental group/condition (as a number, not a range).  
2. An explanation of how the sample size was chosen for each experiment, including power 
analysis where appropriate. 
3. A description of sample collection that enables the reader to understand whether the 
samples represent technical or biological replicates, and an explanation of 
inclusion/exclusion criteria if data samples or subjects were excluded from the analysis 
(outlier criteria). 
4. A description of how samples/animals were allocated to experimental groups and 
processed, and full details of the randomisation procedure used (if relevant).  
5. A statement on whether the investigator was blinded to group assignment and outcome 
assessment, and how this blinding was achieved and evaluated (if relevant).  
6. How many times each experiment shown was replicated (if applicable). 
7. Primary and secondary endpoints/measures should be specified. 
8. Information on the statistical methods and measures used. Authors should indicate whether 
tests were one-sided or two-sided and whether adjustments were made for multiple 
comparisons.  The figure legends should indicate whether medians or means are shown, 
whether error bars are standard deviations (SD), standard error of mean (SEM) or 
confidence intervals, and should include the number of data points per group used to 
generate the figure. 
9. A justification for the appropriateness of the statistical test used should be provided, e.g., 
whether data meet the assumptions of the tests (e.g., normal distribution), whether the 
variation within each group of data has been estimated, and whether the variance observed 
is similar between the groups that are being statistically compared. 
10. Systematic reviews should follow recognised guidelines on conduct and reporting (e.g., 
PRISMA: http://www.prisma-statement.org/). 
 
If the study involves human participants, authors should refer to the relevant reporting guidelines 
from the EQUATOR Network: http://www.equator-network.org/. 
 
Availability of Data 
 
Authors are encouraged to deposit key raw and all processed datasets on which the conclusions of 
the paper rely in publicly available repositories (e.g., using Dryad (http://datadryad.org/), FigShare 
(http://figshare.com/), the Neuroscience Information Network 
(http://www.neuinfo.org/about/index.shtm), OpenfMRI (https://openfmri.org/)).  Alternatively, the 
data may be presented in the main paper or supporting files (e.g., as Supplementary Material), in an 
annotated, machine-readable format whenever possible. Links to deposited datasets or datasets in 
additional files should be explicitly referenced in a section entitled “Availability of data and 
materials”.  
 
If computer code was used to generate results that are central to the paper’s conclusions, a 
statement should be included in the “Availability of data and materials” section to indicate whether 
and how the code can be accessed, including version information as necessary and information on 
possible restrictions on availability. 
 
The editor may specifically request that data be made publicly available. If data cannot be deposited 
in response to such a request, reasons should be provided to the editor and in the “Availability of 
data and materials” section. Under such circumstances, the editor will determine whether the 
manuscript can still be considered for publication. Whether or not made publicly available, data 
should, if ethically appropriate, be made available to other interested scientists upon request.  
  
Appropriate credit should be given to the originators of the raw data. Third parties using the data for 
further analysis and publication should cite the source, which could be the publication in 
Psychopharmacology or elsewhere. 
 
Resources 
 
A description of all resources used with enough information to be uniquely identified should be 
included as a Methods subsection entitled ‘Resources’.   
 Antibodies: source, characteristics, dilutions and how they were validated for the system 
under study should be reported. 
 Cell lines: source, whether identity has been authenticated and whether cell lines were 
tested for mycoplasma contamination should be reported. 
 Animals: source, species, strain, sex, age, husbandry, inbred and strain characteristics of 
transgenic and mutant animals should be reported. 
 Tools (software, databases and services): standard tool names, provider and version 
number, if available, should be reported. 
 Test compounds: source, purity, chemical structure (if not published previously), salt form, 
formulation, vehicle, relevant pharmacokinetic and pharmacodynamics properties in the 
relevant species, e.g., plasma and brain concentration, brain penetration, half-life, stability, 
affinity, selectivity, target engagement (if not published previously) should be reported. For 
information already reported elsewhere, the relevant references should be provided. If that 
information is not available, it remains at the discretion of the editor to decide whether this 
is acceptable. Test compounds should be tested in appropriate concentration or dose-
response. 
Work on the actions of biological extracts of unknown chemical composition, i.e., of a 
mixture of ingredients that is insufficiently defined and/or of unknown concentrations that 
might affect the results, is normally not considered for publication. Clinical studies using 
plant materials with unknown or uncontrolled constituents are discouraged.  Exceptions will 
be made if the plant materials are highly standardized and well characterized (e.g., tobacco; 
cannabis with specified cannabinoid content).  If the pharmacological actions of all the 
relevant components are taken into account, studies with certain biological materials of 
uncertain composition may be considered for publication in Psychopharmacology. 
Authors are also encouraged to provide Research Resource Identifiers (RRIDs) for antibodies, 
organisms and tools (Resource Identification Portal (https://scicrunch.org/resources). 
While we realize that our new guidelines will cause additional work for authors, we consider these 
factors to be crucial elements in the reporting of scientific findings in our field and are convinced 
that the gain of the extra information provided will greatly outweigh this effort and will further 
increase the impact of the articles published in Psychopharmacology.  
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